...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: A clinical future for RVX-2135 or just a pre-clinical tool
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Excellent post tada.

I wonder what "60% better than the drugs on their own" means in terms of cancer. It obviously looks good but is it good enough? I guess if a life is prolonged by 60% it would seem good. But what are the economics of this (probably too soon to tell)? Perhaps this could imply a series of patents...one for each of the drug pairs?

Now that I am thinking about this I wonder what success would be considered or defined for the zen3694 trial?

GLTA

Toinv

6 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply